1. Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting
- Author
-
Qiu, Tingting, Men, Peng, Xu, Xiaohan, Zhai, Suodi, and Cui, Xiangli
- Subjects
aprepitant ,Vomiting ,Antineoplastic Agents ,Nausea ,meta-analysis ,systematic review ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,Antiemetics ,Humans ,chemotherapy-induced nausea and vomiting ,Systematic Review and Meta-Analysis ,Research Article ,Randomized Controlled Trials as Topic - Abstract
Supplemental Digital Content is available in the text, Objective: To systematically evaluate the efficacy and safety of antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) and provide updated information for clinical practice. Methods: Pubmed, Embase, the Cochrane Library, and 3 Chinese literature databases were systematically searched. Randomized controlled trials comparing standard regimen (5-hydroxytryptamine-3 receptor antagonist and glucocorticoid) with aprepitant triple regimen (aprepitant plus the standard regimen) for preventing CINV were screened. Literature selection, data extraction, and quality evaluation were performed by 2 reviewers independently. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated in the meta-analysis using RevMan 5.3 software. Results: A total of 51 randomized controlled trials were finally included in the systematic review. Compared with the standard regimen, the aprepitant triple regimen significantly improved the complete response in the overall (OR 1.88, 95% CI 1.71–2.07), acute (OR 1.96, 95% CI 1.65–2.32) and delayed (OR 1.96, 95% CI 1.70–2.27) phases, regardless of emetogenic risk of chemotherapy. Aprepitant could also significantly enhance the proportions of patients who have no emesis, nausea, or use of rescue medication respectively in the overall, acute and/or delayed phases. Aprepitant was found to be associated with decreased risk of constipation (OR 0.85, 95% CI 0.74–0.97), but increased the incidence of hiccup (OR 1.26, 95% CI 1.05, 1.51). There were no statistically significant differences between the 2 groups on other safety outcomes. Conclusion: The aprepitant triple regimen is effective for the prevention of CINV in patients being treated with moderately or highly emetogenic chemotherapy, and has a significant tendency to reduce the risk of constipation and increase the incidence of hiccup.
- Published
- 2020